IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE
The article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2013-07-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045948752822272 |
|---|---|
| author | E. S. Keshishyan |
| author_facet | E. S. Keshishyan |
| author_sort | E. S. Keshishyan |
| collection | DOAJ |
| description | The article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the development of this infection with unfavorable outcome. The authors present detailed data on epidemiology and world spread of respiratory-syncytial virus infection, its consequences (short-term and long-term) and prevention possibilities. The authors demonstrate efficacy of passive palivizumab (humanized monoclonal antibody) immune prevention on the basis of multiple studies conducted in different countries. The authors show the process of formation of national recommendations for immune prevention of development of this infection. Apart from the main risk groups for the development of respiratory-syncytial virus infection, acknowledged by the scientists, the authors also present additional groups – children with mucoviscidosis, Down’s syndrome, neuromuscular diseases and immune compromised patients due to the primary immune deficiency or in the setting of immune suppressive therapy. |
| format | Article |
| id | doaj-art-affeac2afaee4e1dadc033112f5d541c |
| institution | DOAJ |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2013-07-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-affeac2afaee4e1dadc033112f5d541c2025-08-20T02:54:33ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892013-07-0110461410.15690/pf.v10i4.750191IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCEE. S. Keshishyan0Moscow Research Institute of Pediatrics and Pediatric Surgery of the Ministry of Health of the RFThe article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the development of this infection with unfavorable outcome. The authors present detailed data on epidemiology and world spread of respiratory-syncytial virus infection, its consequences (short-term and long-term) and prevention possibilities. The authors demonstrate efficacy of passive palivizumab (humanized monoclonal antibody) immune prevention on the basis of multiple studies conducted in different countries. The authors show the process of formation of national recommendations for immune prevention of development of this infection. Apart from the main risk groups for the development of respiratory-syncytial virus infection, acknowledged by the scientists, the authors also present additional groups – children with mucoviscidosis, Down’s syndrome, neuromuscular diseases and immune compromised patients due to the primary immune deficiency or in the setting of immune suppressive therapy.https://www.pedpharma.ru/jour/article/view/191respiratory-syncytial virus infectionepidemiologymorbidityconsequencesrisk groupspreventionpalivizumabefficacysafetychildrenneonatespremature infants |
| spellingShingle | E. S. Keshishyan IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE Педиатрическая фармакология respiratory-syncytial virus infection epidemiology morbidity consequences risk groups prevention palivizumab efficacy safety children neonates premature infants |
| title | IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE |
| title_full | IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE |
| title_fullStr | IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE |
| title_full_unstemmed | IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE |
| title_short | IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE |
| title_sort | immune prevention of respiratory syncytial viral infection 15 years of world experience |
| topic | respiratory-syncytial virus infection epidemiology morbidity consequences risk groups prevention palivizumab efficacy safety children neonates premature infants |
| url | https://www.pedpharma.ru/jour/article/view/191 |
| work_keys_str_mv | AT eskeshishyan immunepreventionofrespiratorysyncytialviralinfection15yearsofworldexperience |